That makes PANC even more interesting with angle that Roche could preempt move by TRMS or vice-versa. Thanks for that thought - I had been hearing of squabbles elsewhere also. What I find amusing is that PANC has halved (or so) as their drugs continue to advance. Of course losing the head of the company from a heart attack at a healthcare conference . . .
Market Data 
Markets 
AI
